Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2/HER3 dendritic cell vaccine

A dendritic cell (DC)-based cancer vaccine against the tumor-associated antigens (TAAs) human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and 3 (HER3; ErbB3), with potential immunomodulatory and antineoplastic activities. Upon administration of the anti-HER2/HER3 DC vaccine, the immune system gets exposed to HER2 and HER3, which may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2/3-positive tumor cells. This may result in tumor cell death and decreased tumor growth. HER-2/3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are overexpressed by a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2/3 DC vaccine
anti-HER2/3 DC vaccine
anti-HER2/3 dendritic cell vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search